$1.79
-0.051[-2.77%]
At close: May 10
$1.79
0[0.00%]
After Hours: 4:55PM EDT
Pulmatrix
(NASDAQ:PULM)Latest News for Pulmatrix Stock (NASDAQ:PULM)
Pulmatrix Stock (NASDAQ: PULM)
Categories: All
Friday, May 10, 2024
Thursday, March 28, 2024
Wednesday, February 21, 2024
Monday, January 08, 2024
Thursday, November 09, 2023
Wednesday, October 04, 2023
Tuesday, September 26, 2023
Tuesday, September 19, 2023
Friday, September 08, 2023
Wednesday, August 30, 2023
Tuesday, August 29, 2023
Wednesday, August 23, 2023
Tuesday, August 15, 2023
Thursday, August 10, 2023
Tuesday, July 11, 2023
Thursday, June 15, 2023
Monday, May 15, 2023
Friday, May 12, 2023
Thursday, April 27, 2023
Thursday, March 30, 2023
Monday, March 27, 2023
Wednesday, March 15, 2023
Tuesday, February 07, 2023
Monday, February 06, 2023
Monday, January 23, 2023
Wednesday, January 04, 2023
- Pulmatrix Says Formulated Inhaled Migraine Candidate Safe With Fewer GI Side Effects Compared To IVVandana Singh - Jan 4, 2023, 10:03AM
- Pulmatrix Announces Top Line Results From Phase 1 Study With PUR3100, A Novel Orally Inhaled Dihydroergotamine, For Acute MigraineBenzinga Newsdesk - Jan 4, 2023, 9:07AM
Thursday, November 10, 2022
Monday, September 26, 2022
Thursday, September 22, 2022
Wednesday, September 21, 2022
Thursday, August 25, 2022
Tuesday, August 02, 2022
Tuesday, July 12, 2022
Thursday, May 12, 2022
Wednesday, March 30, 2022
Tuesday, March 29, 2022
Monday, March 21, 2022
Thursday, March 17, 2022
Tuesday, March 01, 2022
Monday, February 28, 2022
Friday, February 25, 2022
- 45 Stocks Moving In Friday's Mid-Day SessionLisa Levin - Feb 25, 2022, 12:02PM
- Stocks That Hit 52-Week Lows On FridayBenzinga Insights - Feb 25, 2022, 10:41AM
- Pulmatrix shares are trading lower after the company reported a 1-for-20 reverse stock split.Benzinga Newsdesk - Feb 25, 2022, 8:37AM
- The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA DecisionShanthi Rexaline - Feb 25, 2022, 8:02AM